Outpatient treatment of osteomyelitis with telavancin.

[1]  Traci S. Aladeen,et al.  Chemical Stability of Telavancin in Elastomeric Pumps☆ , 2015, Current therapeutic research, clinical and experimental.

[2]  J. Karlowsky,et al.  Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Santagati,et al.  Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence. , 2015, International journal of antimicrobial agents.

[4]  K. LaPlante,et al.  Clinical Implications of Vancomycin Heteroresistant and Intermediately Susceptible Staphylococcus aureus , 2015, Pharmacotherapy.

[5]  J. Rello,et al.  The clinical positioning of telavancin in Europe. , 2015, International journal of antimicrobial agents.

[6]  D. Paterson,et al.  Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter , 2012, Antimicrobial Agents and Chemotherapy.

[7]  Kaili Fan,et al.  Successful Treatment of Polymicrobial Calcaneal Osteomyelitis with Telavancin, Rifampin, and Meropenem , 2012, The Annals of pharmacotherapy.

[8]  D. Nathwani,et al.  Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. , 2012, The Journal of antimicrobial chemotherapy.

[9]  D. Warren,et al.  Acute renal insufficiency during telavancin therapy in clinical practice. , 2012, The Journal of antimicrobial chemotherapy.

[10]  M. Gelfand,et al.  Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. , 2011, The Journal of antimicrobial chemotherapy.

[11]  R. Seaton,et al.  Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. , 2011, The Journal of antimicrobial chemotherapy.

[12]  M. Niederman,et al.  Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Calhoun,et al.  Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. , 2008, The Journal of antimicrobial chemotherapy.

[14]  V. Fowler,et al.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Tice,et al.  Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. , 2003, The American journal of medicine.